Earlier this month, Renalytix plc announced a collaboration with Tempus AI to broaden access to the kidney IntelX.dkd blood test for chronic kidney disease patients with type 2 diabetes in the US, alongside Tempus AI’s FDA clearance for an enhanced cardiac imaging platform and new real-world studies validating its diagnostic algorithms.
These developments underscore Tempus AI’s efforts to advance AI-powered diagnostic tools across multiple specialties, highlighting growing adoption of…